Furthermore, delivering Ang (1—7) and PNA5 via inhalation to the lungs may compensate for the endogenous Ang (1—7) depletion due to ACE2 losing its function upon binding to SARS-CoV-2, thus represent a potential therapy for COVID-19 complications (e.g., the cytokine storm) [26]. This evidence concerns the gene ACE2 and COVID-19.